Changing from NAFLD to MASLD: The new definition can more accurately identify individuals at higher risk for diabetes

We were intrigued by the recent name change from NAFLD (non-alcoholic fatty liver disease) to MASLD (metabolic dysfunction-associated steatotic liver disease).1 This transition has garnered significant attention in metabolic research and clinical practice. It is not a mere name change but a choice made after a comprehensive understanding of the disease. As endocrinologists and researchers, we recognize the importance of accurate nomenclature in clinical settings and strive to enhance our understanding of the underlying pathophysiology.